Actinogen Medical

CompanyAustralia

Actinogen Medical develops one asset, in phase 2 (Xanamem in Alzheimer's disease). Mostly small molecule acting on HSD11B1; based in Australia.

1
Asset
Furthest: Phase 2; 1
Trial: 0
Signals

Pipeline

1

Xanamem
Inhibits 11beta-HSD1 to lower cortisol levels in the brain
Phase 2, Small molecule, HSD11B1, Alzheimer's disease, dementia moderate

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Trials1
Similar companies6

Updated 7 Oct 2026 · 2 sources